PDS Biotechnology establishes up to $50M stock offering program
PDS Biotechnology has established an at-the-market offering program to sell up to $50 million in common stock through Yorkville Securities and B. Riley Securities. The sales agreement was signed on June 15, 2026. The company's stock trades on The Nasdaq Capital Market under the symbol PDSB.

*this image is generated using AI for illustrative purposes only.
PDS Biotechnology has established an at-the-market offering program to sell up to $50,000,000 of its common stock. The company entered into a sales agreement with Yorkville Securities and B. Riley Securities on June 15, 2026, to facilitate the offering. This program allows PDS Biotechnology to offer and sell shares through the agents as sales agents or principals from time to time.
The company's common stock is listed on The Nasdaq Capital Market under the symbol "PDSB." As of June 12, 2026, the last reported sale price of the common stock was $1.05 per share. The aggregate offering price for the shares sold under this program will not exceed $50,000,000.
PDS Biotechnology is classified as a "smaller reporting company" under Rule 12b-2 of the Securities Exchange Act of 1934, as amended. Consequently, the company has elected to comply with certain reduced public company reporting requirements.
Key Details of the Offering
| Detail | Information |
|---|---|
| Aggregate Offering Price | Up to $50,000,000 |
| Sales Agents | Yorkville Securities, B. Riley Securities |
| Stock Symbol | PDSB |
| Exchange | The Nasdaq Capital Market |
| Last Reported Sale Price | $1.05 per share (June 12, 2026) |
| Sales Agreement Date | June 15, 2026 |
How will the proceeds from the $50 million offering be allocated to support PDS Biotechnology's clinical development programs?
What impact will the dilution from the share sales have on existing shareholders given the current stock price of $1.05?
What milestones or timelines does PDS Biotechnology aim to achieve with the additional capital raised?
























